Evidence map›Paper›PMID 37964443›Full record

ArticleClinical cardiology2024

Benefit of primary and secondary prophylactic implantable cardioverter defibrillator in elderly patients.

Marie Lewenhardt, Fabienne Kreimer, Assem Aweimer, Andreas Pflaumbaum, Andreas Mügge, Michael Gotzmann

Open access · goldAbstract read
In one paragraph

Article in Clinical cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Benefits of Implantable Cardioverter-Defibrillator for Secondary Prevention in Patients With Organic Heart Disease.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Marie LewenhardtUniversity Hospital St Josef-Hospital Bochum, Cardiology and Rhythmology, Ruhr University, Bochum, Germany.
Fabienne KreimerUniversity Hospital St Josef-Hospital Bochum, Cardiology and Rhythmology, Ruhr University, Bochum, Germany.ORCID http://orcid.org/0000-0003-1400-6254
Assem AweimerUniversity Hospital Bergmannsheil Bochum, Cardiology, Ruhr University, Bochum, Germany.
Andreas PflaumbaumUniversity Hospital St Josef-Hospital Bochum, Cardiology and Rhythmology, Ruhr University, Bochum, Germany.
Andreas MüggeUniversity Hospital St Josef-Hospital Bochum, Cardiology and Rhythmology, Ruhr University, Bochum, Germany.
Michael GotzmannUniversity Hospital St Josef-Hospital Bochum, Cardiology and Rhythmology, Ruhr University, Bochum, Germany.ORCID http://orcid.org/0000-0002-5952-0284
St. Josef-Hospital · DEBG University Hospital Bergmannsheil Bochum · DE

Funding

Open Access Publication Funds of the Ruhr-Universität Bochum
6 · The paper itself

Abstract

backgroundThe benefit of implantable cardioverter-defibrillator (ICD) in elderly patients has been questioned. In the present study, we aimed to analyse the outcome of patients of different age groups with ICD implantation.

methodsWe included all patients who received an ICD in our hospital from 2011 to 2020. Primary endpoints were (1) death from any cause and (2) appropriate ICD therapy (antitachycardia pacing/shock). A "benefit of ICD implantation" was defined as appropriate ICD therapy before death from any cause/or survival. "No benefit of ICD implantation" was defined as death from any cause without prior appropriate ICD therapy.

resultsA total of 422 patients received an ICD (primary prophylaxis n = 323, secondary prophylaxis n = 99). At the time of implantation, 35 patients (8%) were >80 years and 106 patients were >75 years (25%). During the study period of 4.2 ± 3 years, benefit of ICD occurred in 89 patients (21%) and no benefit in 84 patients (20%). In primary prevention, the proportion of patients who had a benefit from ICD implantation decreased with increasing age, and there were no patients who benefited from ICD therapy in the group of patients >80 years. In secondary prophylaxis, the proportion of patients with a benefit from ICD implantation ranged from 20% to 30% in all age groups.

conclusionOur study suggests that the indication of primary prophylactic ICD in elderly and very old patients should be critically assessed. On the other hand, no patient should be denied secondary prophylactic ICD implantation because of age.

Indexed as

Defibrillators, ImplantableAgedDeath, Sudden, CardiacHumansPrimary PreventionRisk FactorsTreatment Outcomeappropriate ICD therapybenefitelderly patientsimplantable cardioverter defibrillator

Identifiers

PMID37964443
PMCPMC10826786
OpenAlexW4388694264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.